Orphan Drugs Market By Therapy (Oncology, Neurology, Endocrinology, Hematology, Cardiovascular, Immunotherapy, Respiratory, and Other Therapies), By Drug Type (Biologics and Non-Biologics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032
- Published date: Sep 2024
- Report ID: 84896
- Number of Pages: 277
- Format:
-
keyboard_arrow_up
-
-
- Hoffmann-La Roche Ltd. (Switzerland)
- Novartis AG (Switzerland)
- Johnson & Johnson Services Inc. (U.S.)
- Merck KGaA (Germany)
- Bristol-Myers Squibb Company (U.S.)
- Pfizer Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Novo Nordisk A/S (Denmark)
- Takeda Pharmaceutical Company Limited (Japan)
- Alexion Pharmaceuticals, Inc. (U.S.)
- Kyowa Kirin Co., Ltd. (Japan)
- GlaxoSmithKline Plc
- AbbVie Inc. Company Profile
- Sanofi S.A
- Amgen Inc. (U.S.)
- Biogen Inc. (U.S.)
- Celldex Therapeutics (U.S.)
- GSK plc. (U.K.)
- Eisai Co., Ltd. (Japan)
- Vertex Pharmaceuticals Incorporated (U.S.)
- Alexion Pharmaceutical Inc.
- ALX Oncology Holdings Inc.
- BioMarin Pharmaceutical Inc.
- Agios Pharmaceuticals Inc.
- DAIICHI SANKYO Company Ltd.
- Other Key Players
Our Clients
- 84896
- Sep 2024
Trusted by more than 17382 organizations globally
✖
Request a Sample Report
We'll get back to you as quickly as possible
